Pacira BioSciences, Inc.

NASDAQ:PCRX

Drug Manufacturers - Specialty & Generic

Healthcare
$36.48 -0.79%

-$0.18 today

Market cap
$1.46B
Beta
0.29
P/E (TTM)
176.9
EPS (TTM)
$0.13
52W Low $18.80High $27.64

Volume 1.81M

Average 0.57M

PCRX Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

Pacira BioSciences, Inc.NASDAQ: PCRX

Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026

Accumulated OCI rises 155.7% from a year ago

Accumulated OCI stood at $3.46M at the end of Q1 FY2026, up 155.7% from a year earlier and down 20.2% from the prior quarter.

Context

  • Accumulated OCI amounted to 0.3% of total assets at the end of Q1 FY2026, up 0.2 pp from a year earlier.
  • Accumulated OCI increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether Accumulated OCI keeps rising in the next quarterly balance sheet after a +155.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.46M-20.2% QoQ
Last fiscal yearDec 2025
$4.33M+1161.5% YoY
Year agoMar 2025
$1.35M+155.7% since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+155.7%——
1 year+1161.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accumulated OCI history

USD · from the balance sheet

Latest · FY2025
4.33M USD
Year-over-year change
+1161.5%
4-year CAGR
+125.6%

Accumulated OCI vs competitors

How PCRX compares with its peers on the latest reported figures

  • PCRX's Mar 2026 Accumulated OCI of $3.46M is the highest of the 4 companies compared; the peer median is -$219K.
  • Its year-over-year change of +155.7% is the highest of 4, against a peer median of -190.9%.
  • Accumulated OCI amounts to 0.3% of total assets for PCRX, versus a peer median of 0.0%.
PCRX Competitors Peer median
Accumulated OCI for PCRX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
PCRXPacira BioSciences, Inc.Mar 2026$3.46M +155.7%—0.3%
SUPNSupernus Pharmaceuticals, Inc.Jun 2026-$138K +31.0%—0.0%
COLLCollegium Pharmaceutical, Inc.Mar 2026-$219K -190.9%—0.0%
SCLXScilex Holding CompanyMar 2026-$6.55M -203.7%—2.2%
LTGOLatigo Biotherapeutics Inc.—— ———
Peer median (excluding PCRX) -$219K-190.9%—0.0%

Competitors are the stored peer set for PCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents585.58M104.14M153.3M276.77M158.55M
Short-term Investments70.83M184.51M125.28M207.84M79.88M
Net Receivables96.32M98.4M105.56M113.3M124.07M
Inventory98.55M96.06M104.35M125.28M152.86M
Other Current Assets100K15.22M21.5M21.93M32.62M
Total Current Assets866.05M498.33M509.99M745.13M547.97M
Property, Plant & Equipment (Net)264.81M254.39M234.95M216.39M182.47M
Goodwill145.18M163.24M163.24M020.21M
Intangible Assets623.97M540.55M483.26M425.97M368.1M
Long-term Investments037.21M2.41M29.45M0
Tax Assets153.36M160.31M144.49M130.38M123.85M
Other Non-current Assets21.99M27.17M36.05M6.2M22.31M
Total Non-current Assets1.21B1.18B1.06B808.39M716.94M
Total Assets2.08B1.68B1.57B1.55B1.26B
Account Payables10.54M15.22M15.7M19.13M15.15M
Short-term Debt374.7M33.65M8.64M201.78M9.84M
Tax Payables429K0000
Deferred Revenue00000
Other Current Liabilities45.49M26.2M42.56M28.81M95.6M
Total Current Liabilities521.12M147.77M97.38M309.92M120.59M
Long-term Debt674.53M655.82M513.8M383.55M408.37M
Deferred Tax Liabilities00004.21M
Deferred Revenue (Non-current)10.13M0000
Other Non-current Liabilities67.45M37.79M38.27M37.06M2.46M
Total Non-current Liabilities823.83M758.42M606.87M465.25M451.22M
Total Liabilities1.34B906.19M704.26M775.17M571.81M
Common Stock45K46K46K47K48K
Retained Earnings(211.9M)(148.75M)(106.8M)(206.36M)(199.32M)
Accumulated OCI167K(380K)247K343K4.33M
Other Stockholders Equity00000
Minority Interest00000
Total Equity730.41M775.01M870.13M778.35M693.11M
Total Debt1.13B763.39M586.04M638.85M454.38M
Net Debt543.27M659.26M432.75M362.08M295.84M

Pacira BioSciences, Inc.

NASDAQ:PCRX

Intrinsic Alpha fair value

Locked

Current Price

$36.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.